Kane Biotech Inc., a biotechnology company trading on the TSX Venture Exchange under the symbol KNE, has announced a significant scientific achievement with the publication of a peer-reviewed article in the journal Frontiers in Antibiotics. This publication highlights crucial advancements in combating antibiotic-tolerant biofilms, a persistent challenge in medical treatments, particularly for chronic wounds.
Key Findings from the Research
The study, authored by researchers from Kane Biotech and the University of Manitoba, focuses on the efficacy of revyve Antimicrobial Wound Gel. This product has demonstrated strong activity against biofilms that have developed high levels of antibiotic tolerance. In laboratory models, revyve effectively eliminated mature biofilms of Staphylococcus aureus and Pseudomonas aeruginosa, even after these bacteria had become resistant to antibiotics.
Impressive Results in Biofilm Reduction
Following pre-treatment with antibiotics, which induced high tolerance in bacterial cells, revyve achieved substantial reductions in surviving populations. The gel often drove bacterial counts below detectable limits within 24 to 72 hours, showcasing its potent antibiofilm properties. These results underscore revyve's potential as a valuable tool in advanced wound care, particularly for improving healing outcomes in chronic, biofilm-laden wounds.
Publication Details and Significance
The article, titled "Efficacy of a Novel Thermo-Reversible Wound Gel Against Antibiotic Tolerant Biofilm," was first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader at Kane Biotech, with contributions from Dr. Sarvesh Logsetty, a renowned burn and trauma surgeon at the Max Rady College of Medicine, University of Manitoba. This research adds to the growing body of evidence supporting innovative approaches to wound and burn management, emphasizing Kane Biotech's leadership in biofilm-targeted therapeutics.
Company Leadership and Future Directions
Dr. Robert Huizinga, Interim CEO of Kane Biotech, commented on the publication, stating, "Having our research published in Frontiers in Antibiotics as an open-access article is an important milestone as we continue to commercialize revyve across wound and burn care markets. This peer-reviewed journal is recognized for its rigorous scientific standards, reinforcing the strength of our technology and our mission to bring advanced, biofilm-targeted solutions to patients."
About Kane Biotech and revyve Products
Kane Biotech specializes in commercializing and developing novel wound care treatments that disrupt biofilms, which are a major contributor to antibiotic resistance in wounds. The revyve product line, including revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser, has received U.S. FDA 510(k) clearance. Additionally, revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are approved by Health Canada, supporting their use in clinical settings.
This publication in Frontiers in Antibiotics, a peer-reviewed, open-access journal focusing on antibiotic development and resistance, marks a pivotal step in validating the effectiveness of revyve in addressing one of the most stubborn issues in modern wound care. As antibiotic resistance continues to pose global health threats, such advancements are critical for improving patient outcomes and advancing medical science.
